The two studies jointly reviewed here demonstrate that for the overall population and especially for older patients (40 years and above) with hormone-receptor positive tumours three cycles of CMF chemotherapy is nearly identical to six cycles, even in the absence of specific additional endocrine therapy. Here, NR4A1 is linked to neoplasm.